Compare HXL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | RNA |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 226.3M |
| IPO Year | 1994 | 2025 |
| Metric | HXL | RNA |
|---|---|---|
| Price | $88.20 | $13.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $88.30 | $69.26 |
| AVG Volume (30 Days) | ★ 845.7K | 141.7K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,893,900,000.00 | N/A |
| Revenue This Year | $10.09 | $88.12 |
| Revenue Next Year | $12.33 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.59 | $11.95 |
| 52 Week High | $98.26 | $73.06 |
| Indicator | HXL | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 38.85 |
| Support Level | $80.59 | $12.56 |
| Resistance Level | $95.16 | $13.97 |
| Average True Range (ATR) | 2.90 | 0.45 |
| MACD | -0.86 | 0.25 |
| Stochastic Oscillator | 37.96 | 28.31 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.